Abstract] In 2014 enterovirus D68 (EV-D68) caused the largest outbreak in the United States since the discovery of the virus. Distinct from before, the 2014 infections were associated with more severe respiratory disease and occasional neurological complications. So far, there are no available vaccines or antivirals for the prophylaxis or treatment of EV-D68 infections. In order to evaluate the antiviral activity of potential inhibitors of EV-D68 replication, a cell-based cytopathic effect (CPE) reduction assay was developed (Sun et al., 2015) .
Note: Hela Rh cells are passaged by 1 in 10, and they will be confluence after 3-4 days.
2. Aspirate the supernatant, wash the cells three times with 10 ml PBS and detach the cells using trypsin at 37 °C about 3-5 min.
3. When the cells are detached, collect the cells with 10 ml growth medium in a 14 ml tube.
Centrifuge the cells for 6 min at 269 x g at room temperature.
4. Re-suspend the cell pellet in 10 ml assay medium (see Recipes).
5. Count the number of cells. Seed the cells into a 96-well plate at a density of 15,000 cells in 100 µl assay medium per well. Incubate the cells for 24 h in the incubator at 37 °C and 5% CO2 to allow the cells to adhere to the plate.
6. Dilute the compounds to the desired start concentration in assay medium. This start concentration should be 6x the desired final concentration to prepare for the 1-in-3 serial dilution.
Add 50 µl of the 6x compound dilution to the 100 µl assay medium in the second column, wells B2 to G2 which seeded with cells (a maximum of 6 compounds, Figure 1 ).
www.bio-protocol.org/e2183 7. Mix the medium of column 2 by gentle pipetting and transfer 50 µl of medium from this column to the next column 3 (B3-G3) (see Figure 2A) ; repeat this up to column 9 (B9-G9). Discard 50 µl of medium from column 9. Column 10 (B10-G10) will be the virus control (VC, assay medium + EV68) and column 11 (B11-G11) will be the cell control (CC, only assay medium).
8. Add 100 µl of EV68 of the desired dilution (MOI = 0.001) to column 2-10 and 100 µl assay medium to column 11 (see Figure 2B) . Wells on the edge of the 96-well plate (see Figure 1 , labelled in grey) contain 200 µl medium but will not be used because edge effects may influence the assay results. 10. Remove the assay medium of all wells in column 2-11 and add 100 µl of 5% MTS/PMS dilution in phenol red-and glutamine-free medium.
11. Following incubation for 40-60 min in the 37 °C 5% CO2 incubator, measure the absorbance in each well of the 96-well plate with a microplate reader at a wavelength of 498 nm.
Data analysis
1. The antiviral activity is calculated as follows:
% antiviral activity = (ODEV68+Compound -ODvc)/(ODCC -ODVC) x 100.
Where, ODCC and ODVC represent average values of optical density (OD) of the cell control (column 11) and the virus control (column 10), respectively, ODEV68+Compound corresponds to the OD value of each infected and treated well.
2. Calculate the EC50 value of each compound, which is defined as the concentration of compound at which the virus-induced CPE is reduced by 50%. This value of antiviral activity is calculated by curve fitting which was generated from GraphPad Prism.
Note: Alternatively, logarithmic interpolation can be used to estimate EC50 values if GraphPad Prism is not available. The below Representative data is shown by logarithmic interpolation.

Representative data
1. % Antiviral activity of each concentration is calculated and showed below: 3. If a 1-to-2 serial dilution of compound is preferred, prepare a 4x concentrated compound dilution and add 100 µl of this compound dilution to column 2; Then transfer 100 µl from well to well to generate the 1:2 dilution series.
4. Because of its low optimum growth temperature, EV-D68 is propagated well at 35 °C. 7. In general, this assay/method is adaptable for other picornaviruses with a few considerations (e.g., cell types, medium and temperature). 
